Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Graier, T; Salmhofer, W; Jonak, C; Weger, W; Zikeli, C; Gruber, B; Sator, P; Prillinger, K; Mlynek, A; Schütz-Bergmayr, M; Richter, L; Ratzinger, G; Sassmann, C; Painsi, C; Häring, N; Wippel-Slupetzky, K; Skvara, H; Trattner, H; Inzinger, M; Bangert, C; Ellersdorfer, C; Falkensteiner, K; Sadoghi, B; Gruber-Wackernagel, A; Hofer, A; Legat, F; Lange-Asschenfeldt, B; Schmuth, M; Vujic, I; Hötzenecker, W; Saxinger, W; Müllegger, R; Quehenberger, F; Wolf, P.
Entwicklung der Patientencharakteristika und der Wirksamkeit der Biologika-Therapie bei Patienten des Österreichischen Psoriasis-Registers von 2004 bis 2022.
J Dtsch Dermatol Ges. 2023; 21(12): 1513-1523.
Doi: 10.1111/ddg.15213_g
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Graier Thomas
- Wolf Peter
- Co-authors Med Uni Graz
- Falkensteiner Katharina Theresia Christina
- Gruber-Wackernagel Alexandra
- Hofer Angelika
- Inzinger Martin
- Legat Franz
- Muellegger Robert
- Painsi Clemens
- Quehenberger Franz
- Sadoghi Birgit
- Salmhofer Wolfgang
- Weger Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background and Objectives: This study analyzed the extent to which the recent introduction of more effective treatments has led to an improvement in real-world psoriasis patients.Patients and Methods: Patient characteristics and the first-year treatment effectiveness in biologic-naive patients have been analyzed since 2004 until now, irrespective of treatment switches.Results: Data from 2,729 patients were eligible for this analysis. The proportion of female patients increased significantly over the years from 29.9% to 36.2% (p < 0.028), while the number of patients with psoriatic arthritis declined from 36.6% to 30.0% (p < 0.001). Moreover, the duration of psoriatic disease and PASI at the start of the treatment significantly decreased. Last observation carrief forward (LOCF) analysis indicated that PASI 90 response increased from 18.9 to 44.6% at 3 months and from 32.9 to 66.8% at 12 months after treatment started. Similary, the PASI <= 3 rates increased from 33.2% to 66.0% at 3 months and from 41.9% to 78.9% at 12 months after the treatment started.Conclusions: The continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes. Though one out of three to five patients, depending on the endpoint selected, nowadays still does not achieve an entirely satisfactory treatment response (i.e., PASI 90 or PASI <= 3).
- Find related publications in this database (Keywords)
- Psoriasis
- psoriatic arthritis
- psoriasis treatment
- biologics